TNGX
Tango Therapeutics, Inc.8.96
-0.16-1.75%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
1.21BP/E (TTM)
-Basic EPS (TTM)
-0.91Dividend Yield
0%Recent Filings
8-K
Q4 loss narrows, cash to 2028
Tango Therapeutics reported Q4 2025 net loss of $38.7M, narrower than prior year, with $343M cash funding operations into 2028. Vopimetostat advances with pivotal 2L pancreatic study and Phase 1/2 combo data slated for 2026, plus new Erasca supply deal. Leadership strengthened: Malte Peters now CEO, Philippe Serrano CRO. Cash lasts through milestones. Risks shadow trial timelines.
10-K
FY2025 results
Tango Therapeutics posted FY2025 net loss of $101.6M on $62.4M collaboration revenue from truncating the Gilead deal, down from $130.3M loss in FY2024. R&D expenses fell 8% to $132.2M as TNG908 and TNG348 programs ended, yet vopimetostat monotherapy shone in Q3 data cutoff with 7.2-month mPFS and 25% ORR in 2L MTAP-deleted pancreatic cancer (n=29), 9.1-month mPFS and 49% ORR in histology-selective cohort (n=37). Q4 advanced combo trials with RevMed's RAS(ON) inhibitors (30 patients enrolled) and TNG456 brain-penetrant dosing. Cash built to $343M into 2028 runway. Clinical delays could stall pivotal plans.
8-K
CEO transition at Tango
Tango Therapeutics' CEO Barbara Weber retired January 8, 2026, transitioning to Executive Chair through year-end with $362K salary. Board member Malte Peters, M.D., succeeded her, securing $720K base, options for 1,650,000 shares, and 350,000 RSUs. Cash stood at $343M as of December 31, 2025 (unaudited). Leadership shift aids clinical push; no disagreements noted.
8-K
Appoints finance expert Sung Lee
Tango Therapeutics expanded its board to eight directors and appointed Sung H. Lee, independent under Nasdaq rules, effective January 2, 2026. The finance veteran, currently CFO at Cytokinetics, gets a stock option for 60,000 shares at $8.93 and 10,000 RSUs vesting over three years, plus $40,000 annual retainer. His strategy expertise bolsters late-stage push for vopimetostat. No committee role yet.
8-K
New $100M ATM with Leerink
Tango Therapeutics terminated its prior $100M Jefferies ATM program on November 18, 2025, effective November 21, and inked a fresh $100M sales agreement with Leerink Partners the same day. Shares will sell at-market or negotiated, with Leerink earning up to 3% commission. No sales guaranteed. New shelf replaces the old seamlessly.
CERO
CERo Therapeutics Holdings, Inc
0.09-0.01
MBIO
Mustang Bio, Inc.
1.07-0.06
MRKR
Marker Therapeutics, Inc.
1.27-0.12
PRLD
Prelude Therapeutics Incorporat
1.99+0.05
RNAZ
TransCode Therapeutics, Inc.
9.11+0.03
RNXT
RenovoRx, Inc.
0.84-0.10
RPTX
Repare Therapeutics Inc.
2.23+0.03
SLXN
Silexion Therapeutics Corp
2.61+0.05
SMMT
Summit Therapeutics Inc.
17.23-0.15
TCRX
TScan Therapeutics, Inc.
0.95-0.01